Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-03-27 1:15 pm Sale | 2026-03-13 | 13G | Syndax Pharmaceuticals, Inc. SNDX | VANGUARD GROUP INC | 0 0.000% | -6,230,334 (Position Closed) | Filing History |
| 2026-02-09 08:08 am Purchase | 2025-12-31 | 13G | Syndax Pharmaceuticals, Inc. SNDX | STATE STREET CORP STT | 4,596,552 5.300% | 4,596,552 (New Position) | Filing History |
| 2026-01-30 2:43 pm Purchase | 2025-12-31 | 13G | Syndax Pharmaceuticals, Inc. SNDX | VANGUARD GROUP INC | 6,230,334 7.160% | 6,230,334 (New Position) | Filing History |
| 2025-08-18 4:53 pm Purchase | 2025-08-15 | 13G | Syndax Pharmaceuticals, Inc. SNDX | Point72 Asset Management L.P. | 4,327,952 5.000% | 2,020,128 (+87.53%) | Filing History |
| 2025-08-14 5:39 pm Sale | 2025-06-30 | 13G | Syndax Pharmaceuticals, Inc. SNDX | Point72 Asset Management L.P. | 2,307,824 2.700% | -1,970,023 (-46.05%) | Filing History |
| 2025-08-13 5:52 pm Purchase | 2025-06-30 | 13G | Syndax Pharmaceuticals, Inc. SNDX | GOLDMAN SACHS GROUP INC GS | 5,581,828 6.500% | 1,071,159 (+23.75%) | Filing History |
| 2025-05-09 12:34 pm Sale | 2025-03-31 | 13G | Syndax Pharmaceuticals, Inc. SNDX | GOLDMAN SACHS GROUP INC GS | 4,510,669 5.200% | -1,442,796 (-24.23%) | Filing History |
| 2025-05-07 11:25 am Sale | 2025-03-31 | 13G | Syndax Pharmaceuticals, Inc. SNDX | MORGAN STANLEY MS | 2,040,013 2.400% | -3,322,156 (-61.96%) | Filing History |
| 2025-04-17 09:35 am Purchase | 2025-03-31 | 13G | Syndax Pharmaceuticals, Inc. SNDX | BlackRock Inc. BLK | 6,744,049 7.800% | 6,744,049 (New Position) | Filing History |
| 2025-03-07 11:13 am Purchase | 2025-02-28 | 13G | Syndax Pharmaceuticals, Inc. SNDX | WELLINGTON MANAGEMENT GROUP LLP | 35,681 0.000% | 35,681 (New Position) | Filing History |
| 2025-02-14 5:18 pm Purchase | 2024-12-31 | 13G | Syndax Pharmaceuticals, Inc. SNDX | Kynam Capital Management LP | 8,520,000 9.980% | 8,520,000 (New Position) | Filing History |
| 2025-02-12 11:39 am Purchase | 2024-12-31 | 13G | Syndax Pharmaceuticals, Inc. SNDX | GOLDMAN SACHS GROUP INC GS | 5,953,465 7.000% | 5,953,465 (New Position) | Filing History |
| 2025-02-05 10:03 am Purchase | 2024-12-31 | 13G | Syndax Pharmaceuticals, Inc. SNDX | MORGAN STANLEY MS | 5,362,169 6.300% | 5,362,169 (New Position) | Filing History |
| 2025-01-22 5:50 pm Purchase | 2025-01-21 | 13G | Syndax Pharmaceuticals, Inc. SNDX | Point72 Asset Management L.P. | 4,277,847 5.000% | 4,277,847 (New Position) | Filing History |
| 2024-12-06 4:28 pm Unchanged | 2024-12-06 | 13G | Syndax Pharmaceuticals, Inc. SNDX | BlackRock Inc. BLK | 0 0.000% | 0 (Unchanged) | Filing |
| 2024-11-08 5:31 pm Unchanged | 2024-11-08 | 13G | Syndax Pharmaceuticals, Inc. SNDX | BlackRock Inc. BLK | 0 0.000% | 0 (Unchanged) | Filing |
| 2024-11-08 10:52 am Unchanged | 2024-11-08 | 13G | Syndax Pharmaceuticals, Inc. SNDX | WELLINGTON MANAGEMENT GROUP LLP | 0 0.000% | 0 (Unchanged) | Filing |
| 2024-10-21 4:11 pm Unchanged | 2024-10-21 | 13G | Syndax Pharmaceuticals, Inc. SNDX | BlackRock Inc. BLK | 0 0.000% | 0 (Unchanged) | Filing |
| 2024-10-18 11:49 am Unchanged | 2024-10-18 | 13G | Syndax Pharmaceuticals, Inc. SNDX | STATE STREET CORP STT | 0 0.000% | 0 (Unchanged) | Filing |
| 2024-02-14 12:50 pm Unchanged | 2024-02-14 | 13G | Syndax Pharmaceuticals, Inc. SNDX | Kynam Capital Management LP | 0 0.000% | 0 (Unchanged) | Filing |